SUSTAINED EFFICACY AND LONG-TERM SAFETY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RESULTS OF A 5-YEAR, OPEN-LABEL EXTENSION STUDY

被引:0
|
作者
Ashina, Messoud [1 ]
Goadsby, Peter J. [2 ,3 ]
Reuter, Uwe [4 ]
Silberstein, Stephen [5 ]
Dodick, David W. [6 ]
Xue, Fei [7 ]
Zhang, Feng [7 ]
Cheng, Sunfa [7 ]
Chou, Denise E. [7 ]
Lima, Gabriel Paiva da Silva [7 ]
机构
[1] Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Dept Neurol,Danish Headache Ctr, Copenhagen, Denmark
[2] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA
[3] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[4] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[5] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[6] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
MTV20-DP-0
引用
收藏
页码:60 / 61
页数:2
相关论文
共 50 条
  • [1] Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+Year Results of a 5-Year, Open-Label Extension Study
    Ashina, M.
    Goadsby, P. J.
    Reuter, U.
    Silberstein, S. D.
    Dodick, D. W.
    Chou, D. E.
    Klatt, J.
    Xue, F.
    Zhang, F.
    Cheng, S.
    Mikol, D. D.
    HEADACHE, 2019, 59 : 25 - 25
  • [2] Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+Year Results of a 5-year, Open-label Treatment Period
    Ashina, Messoud
    Goadsby, Peter
    Reuter, Uwe
    Silberstein, Stephen
    Dodick, David
    Xue, Fei
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel
    NEUROLOGY, 2020, 94 (15)
  • [3] Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+year results of a 5-year, open-label treatment period
    Ashina, Messoud
    Goadsby, Peter J.
    Reuter, Uwe
    Silberstein, Stephen
    Dodick, David W.
    Chou, Denise E.
    Pandhi, Shaloo
    Xue, Fei
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2019, 39 (1_SUPPL) : 365 - 366
  • [4] Consistent efficacy and safety of erenumab in episodic migraine patients during a 5-year, open-label extension study
    Ashina, M.
    Goadsby, P.
    Reuter, U.
    Silberstein, S.
    Dodick, D.
    Zhang, F.
    Xue, F.
    Cheng, S.
    Chou, D.
    Lima, G. Paiva da Silva
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 153 - 154
  • [5] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study
    Ashina, M.
    Goadsby, P. J.
    Reuter, U.
    Silberstein, S. D.
    Dodick, D. W.
    Zhang, F.
    Xui, F.
    Cheng, S.
    Chou, D. E.
    Lima, G. Paiva Da Silva
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 17
  • [6] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study
    Ashina, M.
    Goadsby, P. J.
    Reuter, U.
    Silberstein, S. D.
    Dodick, D. W.
    Zhang, F.
    Xui, F.
    Cheng, S.
    Chou, D. E.
    Lima, G. Paiva Da Silva
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 25 - 26
  • [7] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study
    Ashina, M.
    Goadsby, P. J.
    Reuter, U.
    Silberstein, S. D.
    Dodick, D. W.
    Zhang, F.
    Xue, F.
    Cheng, S.
    Chou, D. E.
    Lima, da Silva G. P.
    HEADACHE, 2021, 61 : 117 - 118
  • [8] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study
    Ashina, Messoud
    Goadsby, Peter
    Reuter, Uwe
    Silberstein, Stephen
    Dodick, David
    Zhang, Feng
    Xue, Fei
    Cheng, Sunfa
    Chou, Denise
    Lima, Gabriel Paiva da Silva
    NEUROLOGY, 2021, 96 (15)
  • [9] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
    Sakai, Fumihiko
    Takeshima, Takao
    Tatsuoka, Yoshihisa
    Hirata, Koichi
    Cheng, Sunfa
    Numachi, Yotaro
    Peng, Cheng
    Xue, Fei
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (04): : 653 - 661
  • [10] Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine
    Ashina, Messoud
    Goadsby, Peter J.
    Reuter, Uwe
    Silberstein, Stephen
    Dodick, David
    Rippon, Gregory A.
    Klatt, Jan
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19